The nation of Zimbabwe has rejected a significant American health deal worth $367m (272 million pounds) over five years over Washington's demand for sensitive information.
The decision came to light following a official document dated December was leaked, which showed President Emmerson Mnangagwa felt the deal was "skewed".
A government representative has since explained that the US was requesting health data for scientific study and commercial gain but was not willing to share the resulting advantages from future vaccines.
"We must now begin the difficult and regrettable task of scaling back our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the US had donated over $1.9bn in health funding to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has called for further talks to reach a agreement agreeable to both sides so the nation's vital HIV programme can be sustained.
Wider Background
This development follows a similar situation in Kenya, where a court suspended a related deal with the US after legal challenges were filed about the safety of citizens' health data.
After resuming office recently, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
The agency had overseen assistance for the American government, but Trump claimed its expenditure was "wasteful" and his administration was seeking government-to-government deals to enhance transparency and responsibility.
According to statements, Sixteen African countries have so far signed similar health pacts, constituting more than $18.3bn in new funding.
Details of the Declined Deal
The money for Zimbabwe was intended to gone towards "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this cooperation might have yielded extraordinary benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently on antiretroviral therapy via US-supported programmes," the Ambassador added.
However, official spokesman Nick Mangwana maintained the proposed deal was "unequal".
"Our nation was requested to provide its biological resources and data indefinitely, without any corresponding assurance of benefiting from any scientific breakthroughs – like new medicines or tests – that could result from that shared data," he stated.
"In essence, our country would provide the basic resources for scientific discovery with no assurance that the resulting innovations would be available to our population if a new pandemic emerge."
Sovereignty and Global Health
He also said that the US's withdrawal from the global health body and its push of bilateral health agreements were disrupting systems already set up through the global organization.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme designed to manage future pandemics.
"This mechanism is designed to guarantee that when a nation contributes its data, the resulting advantages – including vaccines and treatments – are distributed fairly, not commercialised solely by those with the funds to develop them."
The government's concerns over the US deal "must not be interpreted as opposition to America," he added.
"We welcome ongoing discussions with our American counterparts on how subsequent collaboration could be structured in a way that honours the sovereignty and interests of each country."
Health Experts Reaction
A leading public health body expressed it acknowledged the government's concerns, but suggested that talks should continue given that much of the nation's Aids initiatives depended on international support.
"Where specific concerns exist, such as those relating to information security or agreement terms, these can often be addressed through technical clarification and mutually agreed protections," the group said.
The situation underscores the ongoing debate between accepting vital foreign assistance and protecting national sovereignty in an increasingly data-driven world.